The Chinese Expert Consensus on Antiangiogenic Drug Therapy for Advanced Non-Small Cell Lung Cancer (2020 Edition) was officially released to help improve the level of clinical treatment of late NSCLC.

On the occasion of CSCO 2020, on September 14th, the Chinese Expert Consensus on Anti-Angiogenesic Drug Therapy for Advanced Non-Small Cell Lung Cancer (2020 Edition) (hereinafter referred to as the Consensus) was officially launched in Shanghai, led by the Committee of Experts on Vascular Targeting Therapy of the Chinese Society of Clinical Oncology (CSCO) and the Committee of Experts on Non-Small Cell Lung Cancer.
consensus on the treatment of advanced non-small cell lung cancer (NSCLC) put forward the latest expert consensus and clinical guidance.
compared to the 2019 edition, the latest edition of consensus fully considers the particularities of clinical treatment in China and includes a number of clinical studies or analyses initiated by Chinese experts.
focused on updating the combination of anti-angiogenesis drug immune program (atilijudium monoantigen and chemotherapy) as a first-line treatment option for late-stage NSCLC;
with the rise of small molecule-targeted drugs in recent years, Consensus has increased the exploratory progress in combined immunotherapy with small molecule-targeted drugs such as atrotinie and apatinists.
it is understood that the latest edition of the Consensus will be published in the Chinese Journal of Oncology and the Chinese Medical Journal in December 2020.
The "Consensus" conference experts gathered, editorial board leader, Shanghai Jiaotong University affiliated chest hospital Professor Han Baohui, Tongji University affiliated shanghai lung hospital Professor Zhou Caishou, "Chinese Medical Journal" editorial director Lu Xiangzheng delivered a speech, in addition, Shanghai Jiaotong University affiliated chest hospital Professor Tianqing, Fudan University affiliated Zhongshan Hospital Hu Jie Professor Liang Xiaohua of Huashan Hospital affiliated with Fudan University, Professor Su Chunxia of Shanghai Lung Hospital affiliated with Tongji University, Professor Yu Yuansheng of Long March Hospital affiliated with Naval Military Medical University, and Professor Zhong Hua of Shanghai Jiaotong University Affiliated Chest Hospital (name in alphabetical order) also attended the press conference to witness this important moment in the diagnosis and development of advanced non-small cell lung cancer.
consensus update, to help the late NSCLC clinical treatment level to improve lung cancer is currently the world's most common and highest fatality of malignant tumors.
statistics, there will be about 774,000 new cases of lung cancer in China in 2018, and about 690,000 people will die of lung cancer.
non-small cell lung cancer (NSCLC) is the most common histological type of lung cancer, accounting for more than 80% of lung cancer cases.
because of the high invasiveness of NSCLC and the lack of effective early screening program, 68% of lung cancer patients in China are diagnosed at a late stage.
, Health China Action (2019-2030) has explicitly identified cancer prevention and treatment as one of the major initiatives.
, Professor Han Baohui, said:
The level of clinical cancer treatment in China is very different, and the Chinese Society of Clinical Oncology has been committed to improving the overall level of treatment of clinical tumors in China.
, anti-angiogenesic drugs play an important role in the treatment of late NSCLC in China, especially the clinical research initiated by many Chinese experts has entered the clinical practice.
"China Expert Consensus on Antiangiogenic Drug Therapy for Advanced Non-Small Cell Lung Cancer" has an important guiding effect on the clinical practice of late NSCLC.
The Consensus is updated annually, and we hope that through the continuous updating of the Consensus, we can provide international advanced treatment strategies and professional guidance for lung cancer treatment in China, improve the clinical treatment capacity and standardized treatment level of the vast number of primary hospitals and primary doctors in China, promote the popularization of anti-angiogenesic drugs, and contribute to the realization of 'Healthy China 2030'.
"The Chinese Expert Consensus on Antiangiogenic Drug Therapy for Advanced Non-Small Cell Lung Cancer is based on the framework of the CSCO Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer (hereinafter referred to as the Guidelines), and is based on more meta-analysis, real-world data and clinical practice," said Professor Zhou Caissan. the new edition of
Consensus further affirms the indispensable position of anti-angiogenesic drugs in the treatment of advanced non-small cell lung cancer (NSCLC), points out the development direction for late NSCLC treatment, and also provides theoretical reference for more primary hospital doctors, as well as professional interpretation of the guidelines recommended to help improve the overall level of lung cancer treatment in China.
" Director Lu Xiangzheng said: The new version of the Consensus brings together two CSCO expert committees, 46 expert group members to compile nearly a year of published high-quality clinical research evidence, a total of nearly 200 English literature and nearly 300 Chinese literature, China's anti-angiogenesic drugs in the treatment of advanced non-small cell lung cancer status and application of a systematic combing.
Of the 65 research evidence cited in the new edition of the consensus, nearly 30% (29) are clinical studies or analyses led by Chinese experts, and the update of this "consensus" with Chinese clinical characteristics will greatly promote the standardized diagnosis and treatment of anti-angiogenesic drugs for this type of disease, and the journal will continue to vigorously promote the Consensus in the future to help improve the level of lung cancer treatment in China.
The joint anti-angiogenesic immune T-A first into the Consensus", the late NSCLC first-line treatment and the addition of the new army as one of the sponsors of the Consensus, Professor Han Baohui at the press conference on the "Consensus" of the significance of the release of a detailed explanation.
, Professor Han Baohui, said: "With the rapid development of lung cancer, the model of joint application has become the direction of NSCLC.
immunotherapy is currently the focus of global cancer treatment, while the accessability of immunotherapy drugs in China is steadily improving, the new version of the Consensus will be the first anti-angiogenespheric combined immuno-A treatment program introduced in it, with atili-pearl monoantigenated beva bead monoanti, carbain and yew alcohol, as a late non-scale NSCLC first-line treatment recommended.
based on the results of the large-scale IMpower150 study, the T-A model can further extend the survival of patients, with a medium total survival (OS) of 19.8 months.
In addition, a number of small sample size exploratory studies initiated by domestic experts on the combined immunotherapy of small-molecule multi-target anti-angiogenesic drugs also achieved good results, further confirming that anti-angiogenesic joint immunity has a positive effect on the treatment of late NSCLC.
" at the same time, the Consensus recommends a combined anti-angiogenic immunotherapy for atilijutin monoantigen, carbatin and yew alcohol, which can be used as a first-line treatment option for patients with advanced non-scale NSCLC with liver metastasis. and patients with EGFR-sensitive mutations who developed disease progression after TKI treatment, and who had no evidence of T790M mutations, or patients with T790M mutations who failed treatment with Oghithini, ruled out other possible treatment options after targeted drug therapy.
anti-angiogenesic joint targeted therapy, the opening of a new era of EGFR sensitive mutation late NSCLC treatment with the advent of the era of precision medicine, the understanding of the target more in-depth, more targeted treatment methods continue to emerge, for cancer patients to bring more survival benefits.
Among them, antiangiogenic drug joint targeting therapy is regarded as an important choice for advanced NSCLC first-line treatment of sensitive EGFR mutations -- this Consensus update emphasizes that antiangiogenic drug co-targeting drugs can benefit patients who drive gene-positive. "A number of international and domestic clinical studies have confirmed that the combined angiogenesic targeting treatment programme represented by the Erotini combined beva bead monoantigen can delay drug resistance to targeted drugs and significantly prolong the median progression-free survival (PFS) in patients with EGFR mutation-positive NSCLC," said Professor
.
therefore, the Consensus recommends that in patients with advanced non-scale NSCLC with EGFR-sensitive mutations, erotinib combined beva bead monoantigen is recommended as a first-line treatment option (level II recommendation, Class 1A evidence).
" In addition, Beval pearl single anti-joint Giftonini is also included in the Consensus.
Anti-angiogenesic drugs continue to work hard, escorting the late NSCLC special population This Consensus, in addition to the first-line treatment program to update, but also the second and third line and accompanied by brain metastasis, radioactive brain injury and other late NSCLC specific population treatment program has been updated recommended.
take the late NSCLC patients with radioactive brain injury as an example, radioactive brain injury is a disease in which the brain metastasis cooker produces symptoms of central nervous system damage after radiation therapy, and is a serious complication after radiation therapy in tumor patients.
Consensus recommends the use of beva bead monoantigen can alleviate radioactive brain damage in patients with advanced NSCLC brain metastasis tumor weekly edema, reduce the incidence of intracranial bleeding, severe hypertension and other symptoms, for such patient groups to provide a fuller and more comprehensive treatment options.
From first-line treatment to second- and third-line therapy, and even treatment for specific populations, the new edition of Consensus fully considers the various applications of anti-angiogenesic drugs in late-stage NSCLC treatment, creating a new treatment pattern for Chinese doctors.
looking to the future, for the application of anti-angiogenesic drugs in patients with late NSCLC, I hope that with the deepening of its research and practice at home and abroad, the application of anti-angiogenesic drugs in the future will be more extensive, benefiting more lung cancer patients.
source: Medical Valley.com Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Met Medical" or "Source: MedSci Original" are owned by Mets Medical and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
reproduce content at the same time does not represent the position of this site.
leave a message here.